Mitral regurgitation (MR) is the most prevalent valvular heart disease in the U.S., affecting approximately 1.7% of the population. MR prevalence increases with age, rising from 0.5% among 18-44 year olds to 9.3% among those aged 75 years and older [1,2]. There are 4.1 million patients in the US with moderate to severe MR requiring treatment. However, only approximately 30,000 patients in the U.S. undergo surgery for MR each year . The vast majority of patients are not treated today because of the concerns about procedural complexity and patient safety during open-heart surgery. Transcatheter mitral valve repair (TMVRep) or replacement (TMVR) offer less invasive treatment options for MR patients. However, after more than a decade of development, the field of transcatheter mitral valve therapy is still in its infancy. Many of the current TMVRep and TMVR devices have dismal clinical results.
Sutra TMVR is a percutaneous, transcatheter bioprosthetic MV replacement system that bridges the best aspects of TMVR and TMVRep approaches.
 Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation 2017;135:e146-e603.
 Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet 2006;368:1005-11.
 Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation 2010;121:e46-e215.
This project is currently funded by NIH SBIR RHL140835
Note: Sutra TMVR is not approved for investigational use or sale in the United States.